Clary Estes on Muck Rack

Clary Estes

Verified
As seen in: Bio News, Medium, Forbes, PetaPixel, Lexington Herald-Leader, EIN News, The Lane Report, Blurred Culture, Business Lexington

Get in touch with Clary

Contact Clary, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Clary Estes’s Journalist Portfolio

Clary Estes

Clary Estes

Clary Estes is a documentary photographer and writer from Central Kentucky who works internationally.

View article →

Articles

BIO 2026: As capital returns, focus on quality over quantity

|
By Clary Estes Verified
| Bio News
“Last year was a very business-as-usual year,” said Daniel Chancellor, VP of Thought Leadership at Norstella, “and has been followed by a year that was totally anything but.” His comments came during the presentation of a new report, The State of Emerging Biotech: Investment, Deals, and Pipelines Report, produced by the Biotechnology Innovation Organization (BIO) and Norstella and released at the 2026 BIO International Convention on June 23.
Open in Who Shared Issue with article?

BIO 2026: Where AI is delivering – and where biotech must go next

|
By Clary Estes Verified
| EIN News
Artificial Intelligence is on the lips of everyone at the 2026 BIO International Convention. And as the second-annual AI Summit began on June 22, everyone was talking about one headline in particular: the $2.5 billion deal between Insilico Medicine and SK Biopharmaceuticals. The deal leverages Insilico’s Pharma.AI platform with SK Biopharmaceuticals’ expertise. With this ramp-up in technology and dealmaking, the AI Summit explored several key questions. Where is AI delivering?
Open in Who Shared Issue with article?

BIO 2026: Where AI is delivering – and where biotech must go next

|
By Clary Estes Verified
| Bio News
Artificial Intelligence is on the lips of everyone at the 2026 BIO International Convention. And as the second-annual AI Summit began on June 22, everyone was talking about one headline in particular: the $2.5 billion deal between Insilico Medicine and SK Biopharmaceuticals. The deal leverages Insilico’s Pharma.AI platform with SK Biopharmaceuticals’ expertise. With this ramp-up in technology and dealmaking, the AI Summit explored several key questions. Where is AI delivering?
Open in Who Shared Issue with article?
See all 504 licensed articles (505 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified